MXPA02011554A - Combinacion de secretagogos de hormona del crecimiento y antidepresivos. - Google Patents
Combinacion de secretagogos de hormona del crecimiento y antidepresivos.Info
- Publication number
- MXPA02011554A MXPA02011554A MXPA02011554A MXPA02011554A MXPA02011554A MX PA02011554 A MXPA02011554 A MX PA02011554A MX PA02011554 A MXPA02011554 A MX PA02011554A MX PA02011554 A MXPA02011554 A MX PA02011554A MX PA02011554 A MXPA02011554 A MX PA02011554A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrug
- methods
- kits
- growth hormone
- medical procedure
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 5
- 229940005513 antidepressants Drugs 0.000 title abstract 5
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 2
- 229960002073 sertraline Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 230000001925 catabolic effect Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003335 secondary amines Chemical class 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invencion esta dirigida a combinaciones que comprenden un secretagogo de hormona del crecimiento, un profarmaco de este o una sal farmaceuticamente aceptable del citado secretagogo de la hormona de crecimiento o del citado profarmaco y un antidepresivo, un profarmaco de este o una sal farmaceuticamente aceptable del citado antidepresivo o del citado profarmaco y a composiciones farmaceuticas y estuches que comprenden dichas combinaciones; los antidepresivos dentro del alcance de esta invencion incluyen inhibidores de la recaptacion de norepinefrina (por ejemplo compuestos triciclicos con amina secundaria o terciaria) inhibidores selectivos de la recaptacion de sertralina, agentes que son inhibidores de la recaptacion de norepinefrina/sertralina combinados, inhibidores de monoaminooxidasa y antidepresivos atipicos; esta invencion esta dirigida tambien a procedimientos de mejora del estado fisico y/o psicologico de un paciente sometido a un procedimiento medico, a procedimientos de tratamiento de la fragilidad musculosesqueletica, a procedimientos de tratamiento de la insuficiencia cardiaca congestiva y a procedimientos de atenuacion de la respuesta catabolica proteinica despues de una operacion importante, que comprenden la administracion de dicha combinacion; particularmente, esta invencion se refiere a composiciones y estuches tales que mejoran la funcion cardiaca, el metabolismo, el tono muscular y/o el estado mental de pacientes sometidos a un procedimiento medico; las composiciones y estuches de esta invencion son tambien utiles para el tratamiento de trastornos del sistema nervioso central en pacientes sometidos a un procedimiento medico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20701700P | 2000-05-25 | 2000-05-25 | |
| PCT/IB2001/000815 WO2001089570A2 (en) | 2000-05-25 | 2001-05-10 | Combination of growth hormone secretagogues and antidepressants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02011554A true MXPA02011554A (es) | 2003-04-25 |
Family
ID=22768871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02011554A MXPA02011554A (es) | 2000-05-25 | 2001-05-10 | Combinacion de secretagogos de hormona del crecimiento y antidepresivos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020002137A1 (es) |
| EP (1) | EP1284753A2 (es) |
| JP (1) | JP2003534294A (es) |
| AR (1) | AR028620A1 (es) |
| AU (1) | AU2001255013A1 (es) |
| BR (1) | BR0111002A (es) |
| CA (1) | CA2408036A1 (es) |
| DO (1) | DOP2001000154A (es) |
| EC (1) | ECSP014082A (es) |
| GT (1) | GT200100089A (es) |
| MX (1) | MXPA02011554A (es) |
| PA (1) | PA8517701A1 (es) |
| PE (1) | PE20011262A1 (es) |
| SV (1) | SV2001000465A (es) |
| TN (1) | TNSN01076A1 (es) |
| UY (1) | UY26731A1 (es) |
| WO (1) | WO2001089570A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1661898A4 (en) * | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| AU2008241532A1 (en) | 2007-02-09 | 2008-10-30 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| CL2008003749A1 (es) | 2007-12-17 | 2010-01-15 | Janssen Pharmaceutica Nv | Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras. |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| EP2852591A1 (en) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| JP2023548031A (ja) | 2020-10-21 | 2023-11-15 | アリゴス セラピューティクス インコーポレイテッド | 二環式化合物 |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
-
2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/es unknown
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/es unknown
- 2001-05-10 EP EP01928149A patent/EP1284753A2/en not_active Withdrawn
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/ja active Pending
- 2001-05-10 CA CA002408036A patent/CA2408036A1/en not_active Abandoned
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/pt not_active Application Discontinuation
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/en not_active Application Discontinuation
- 2001-05-17 GT GT200100089A patent/GT200100089A/es unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/es not_active Application Discontinuation
- 2001-05-24 AR ARP010102481A patent/AR028620A1/es not_active Application Discontinuation
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/fr unknown
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/es unknown
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/es unknown
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/es unknown
- 2001-05-25 UY UY26731A patent/UY26731A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN01076A1 (fr) | 2005-11-10 |
| UY26731A1 (es) | 2001-12-28 |
| US20020002137A1 (en) | 2002-01-03 |
| JP2003534294A (ja) | 2003-11-18 |
| ECSP014082A (es) | 2002-04-23 |
| SV2001000465A (es) | 2001-07-03 |
| AU2001255013A1 (en) | 2001-12-03 |
| DOP2001000154A (es) | 2002-05-15 |
| WO2001089570A2 (en) | 2001-11-29 |
| AR028620A1 (es) | 2003-05-14 |
| CA2408036A1 (en) | 2001-11-29 |
| GT200100089A (es) | 2002-01-11 |
| BR0111002A (pt) | 2003-04-15 |
| EP1284753A2 (en) | 2003-02-26 |
| PA8517701A1 (es) | 2002-12-30 |
| PE20011262A1 (es) | 2001-12-11 |
| WO2001089570A3 (en) | 2002-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DeBattista et al. | Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study | |
| Rush et al. | Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study | |
| Trivedi et al. | Original Research A Randomized Controlled Trial of the Efficacy and Safety | |
| Menza et al. | Modafinil augmentation of antidepressant treatment in depression | |
| DE602006021444D1 (de) | Therapie zur behandlung der überaktiven blase | |
| Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
| MXPA02011554A (es) | Combinacion de secretagogos de hormona del crecimiento y antidepresivos. | |
| ECSP055839A (es) | COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD | |
| Aizenberg et al. | Mianserin, a 5-HT2a/2c and α2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors | |
| WO2002041883A3 (en) | As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation | |
| NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
| Nelson et al. | The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials | |
| HUP0102511A2 (hu) | Kombinált gyógykezelés bipoláris betegségek kezelésére | |
| SE9501567D0 (sv) | A new combination | |
| Hensley et al. | SSRI sexual dysfunction: a female perspective | |
| HUP0302436A2 (hu) | Antidepresszáns gyógyszerek által kiváltott szexuális rendellenességek kezelése apomorfinnal | |
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| WO2004100937B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| Athanasiadis | Premature ejaculation: is it a biogenic or a psychogenic disorder? | |
| HUP0002643A2 (hu) | Szívrendellenességek kezelése és megelőzése SSRI-k alkalmazásával | |
| SE9803157D0 (sv) | A new composition | |
| Miner et al. | Distinguishing premature ejaculation from other sexual function disorders | |
| Belli et al. | Escıtalopram Related Erectıle Dysfunctıon and Spontaneous Ejaculatıon durıng Mıcturıtıon | |
| Klint et al. | Lack of typical SSRI-related adverse effects and sexual dysfunction with mirtazapine is related to specific blockade of 5-HT2 and 5-HT3 receptors |